Recent Updates
Recently added Catalysts
JSPR Negative Sentiment

JASPER CLASS ACTION: Bragar Eagel & Squire, P.C. Reminds Jasper Stockholders of the November 18th Deadline for Filed Class Action Lawsuit

Key Takeaway: A class action lawsuit has been filed against Jasper Therapeutics, Inc. (NASDAQ: JSPR) by the law firm Bragar Eagel & Squire, P.C., on behalf of investors who acquired securities between November 30, 2023, and July 3, 2025. The lawsuit claims the company made false and misleading statements about its operations and compliance, particularly regarding third-party manufacturing practices and the clinical prospects of its product briquilimab. Investors have until November 18, 2025, to apply as lead plaintiffs.
Price reaction · baseline $2.34 (2025-10-28 close) · hit after-hours · 2 other JSPR headline(s) in the window, move may be shared
day 0 close · peak
+0.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges that Jasper made materially false and misleading statements.
  • It claims lack of necessary controls and procedures for third-party manufacturers.
  • The company's product, briquilimab, may face increased regulatory and commercial risks.
  • Potential disruptive cost-reduction measures could impact the company's financial outlook.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
7.8%
average across 5 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
Isradipine
Phase 1 · Nicotine Dependence

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ:JSPR) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”).
Investors have until November 18, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Jasper shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

Who should contact Brandon Walker regarding Jasper losses?

Investors who suffered losses from Jasper securities should reach out.

What time period is covered by the class action against Jasper?

The class action covers purchases of Jasper securities from Nov 30, 2023, to July 3, 2025.

What allegations are made against Jasper in the lawsuit?

The lawsuit claims Jasper made false statements about compliance and product safety.

When is the deadline to apply as a lead plaintiff?

Investors have until November 18, 2025, to apply to be lead plaintiffs.

How can investors contact Bragar Eagel & Squire?

Investors can call (212) 355-4648 or email investigations@bespc.com for inquiries.

Last updated: Oct 29, 2025